Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
NegativeFinancial Markets

Aspire Biopharma is facing a potential delisting from Nasdaq due to a compliance shortfall, which raises concerns about its financial health and future operations. This situation is significant as it could impact investor confidence and the company's ability to raise capital, ultimately affecting its research and development efforts.
— Curated by the World Pulse Now AI Editorial System